Generally, patients with pathological BRCA mutations present the best benefit from PARPi therapy, but clinical studies demonstrated the efficacy of PARPis against cancers presenting defects in HR due to other genes, such as ATM and partner and localizer of BRCA2 (PALB2). The gene discussed is BRCA2; the disease is cancer.